About Us

Company Profile

LeadArt Biotechnologies Inc., founded in 2022, is a subsidiary company of Ningbo LeadArt Biotechnology Co., LTD., founded in 2017. LeadArt is the first biotechnology company in China and one of the few in the world that has mastered breakthrough chemical proteomics technology. The company also has mature biotechnology automation equipment development and proven productization capabilities. Powered with state-of-art biotechnology and advanced automation technology, LeadArt is building the largest and leading live cell target-probe database in the world and aspired to expand the drug target space and speed up drug discovery.

Team

Leadership Team
Advisory Team

Dr. Feng Ni

Co-Founder, Chief Executive Officer

Chemoproteomics and Medicinal Chemistry expert with 15+ years of experience B.S. Chemistry, Xiamen University Ph.D. Organic Chemistry, Xiamen University 2010-2017 Senior Scientist, University of Southern California 2017-2023 Anzhong Chair Professor, the Institute of New Drug Technology, Ningbo University

Dr. Yufeng Zhao

Co-Founder, Board Director

Member of the Chinese Academy of Sciences, More than 30 years of experience in chemical biology research and drug discovery, Dean of the Institute of New Drug Technology, Ningbo University, Professors of Tsinghua University, Xiamen University, Zhengzhou University

JIe Yan

Co-Founder, Chief Operating Officer

14 years + of drug development experiences in the biopharma industry including Amgen and Lexicon Pharmaceuticals in the USA, Co-founder of BioSpark Group in the USA. MS of Iowa State University, Candidate of Doctor of Engineering of Tsinghua University

Dr. Jiaming He

Chief Engineer, Founder of Keyone Biomedical

20+ years of R&D experience in IT & AI projects, Research and development of biomedical medical automation equipment, Master and Ph.D. of Zhejiang University, Second Prize of National Science and Technology Progress Award

Frank Ebetino

Drug Development Expert

President of BioVinc USA, former director of the Procter & Gamble's drug research and development department in US, with complete drug development process experience, world authority in phosphorus chemistry

Xi Ning

Expert In Medical Chemistry

Chief Scientific Officer of Guangdong Dongyangguang Pharmaceutical, National Distinguished Expert, Professor of Ningbo University, Former Senior Scientist of the Medicinal Chemistry Department of Amgen

Chen Yuzong

Expert In Chemical Informatics /AI

Professor of Singapore National Unversity, Computational Biology, Computer Aided Drug Design and Bioinformatics Authority

History

2022

2021

2020

2018

2017

Established research and Development and business center in Boston, USA

2022-06

Established the automation production center in Cixi, China

2022-08

Completed the Pre-A round of financing

2022-08

Major Science and Technology Breakthrough Award, Ningbo, China

2021-09

Acquired Keyone Biomedical and established automation team

2020-10

Moved in to LeadArt R&D headquarter

2020-11

Angel round financing

2018-05

Shanglin Elite Entrepreneurship Award

2018-07

Ningbo 3315 Entrepreneurship Award

2018-09

Established LeadArt Technology in USA

2017-04-01

Established Ningbo LeadArt Biotechnology Co Ltd

2017-06-03

Strategic Partners

Collabrators

LeadArt is a leading chemoproteomics and automation platform, and we have established multiple business and collaborations with universities, research institutes, biotech, biopharma, and medical companies.